- age less than 18 years - known allergy to vitamin c - inability to obtain consent from patient or next of kin - presence of diabetic ketoacidosis - any history of oxalate stones at any time - patients with kidney disease improving global outcomes (kdigo), ckd stage 4 (egfr < 30 ml/min, ckd stage 5 and end-stage renal disease on dialysis patients are excluded. - patients with acute kidney injury, stage 3 (see page 28). - pregnant, or lactating - known diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency - patients who received the following medications within 7 days prior to enrollment, or plan to receive during enrollment, or 7 days after enrollment: aluminum hydroxide, bortezomib, copper, deferoxamine, amphetamines including derivatives such as fluphenazine. - patients with active sickle cell crisis - prisoners

- age less than 18 years - known allergy to vitamin c - inability to obtain consent from patient or next of kin - presence of diabetic ketoacidosis - any history of oxalate stones at any time - patients with kidney disease improving global outcomes (kdigo), ckd stage 4 (egfr < 30 ml/min, ckd stage 5 and end-stage renal disease on dialysis patients are excluded. - patients with acute kidney injury, stage 3 (see page 28). - pregnant, or lactating - known diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency - patients who received the following medications within 7 days prior to enrollment, or plan to receive during enrollment, or 7 days after enrollment: aluminum hydroxide, bortezomib, copper, deferoxamine, amphetamines including derivatives such as fluphenazine. - patients with active sickle cell crisis - prisoners

- known allergy to vitamin c - inability to obtain consent from patient or next of kin - presence of diabetic ketoacidosis - active kidney stone(s) - pregnant - incarcerated

- known allergy to vitamin c - inability to obtain consent from patient or next of kin - presence of diabetic ketoacidosis - active kidney stone(s) - pregnant - incarcerated